Health
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma (NCT07464925).
About this update from Biolinerx Ltd.
[{"type":"text","content":"GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"GLIX1 has demonstrated potent anti-tumor activity in multiple GBM models, excellent blood-brain barrier penetration and a favorable safety profile in preclinical toxicology studies","length":180,"tagName":"p","attribs":{}},{"type":"text","content":"Study is being conducted by world-leading glioblastoma investigators, led by Dr. Roger Stupp ","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"TEL AVIV, Israel, March 26, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma (NCT07464925).","length":383,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"BioLineRx Logo","displaySize":"","headline":null,"caption":"BioLineRx Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I2d.qLr3NvmwANgRGS5CpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OQ--/https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a","width":400,"height":107}}},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"GLIX1 is an oral small molecule with a novel mechanism of action applicable to a broad range of cancers. By restoring TET2 activity, GLIX1 selectively targets DNA damage repair in cancer cells only. GBM was selected as the first indication for GLIX1 due to the low level of TET2 activity in this aggressive brain cancer, for which there remains a high unmet medical need for novel and more effective treatments. In extensive preclinical studies, including in-vivo GBM models, GLIX1 demonstrated potent anti-tumor activity and excellent blood-brain-barrier penetration, combined with a favorable safety profile in toxicology studies.","length":632,"tagName":"p"},{"type":"text","content":"Three renow...